Price T Rowe Associates Inc. MD Increases Stock Position in Qiagen (NYSE:QGEN)

Price T Rowe Associates Inc. MD boosted its position in shares of Qiagen (NYSE:QGEN - Free Report) by 23.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 142,794 shares of the company's stock after buying an additional 27,518 shares during the period. Price T Rowe Associates Inc. MD owned approximately 0.06% of Qiagen worth $6,359,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in QGEN. Barclays PLC lifted its stake in Qiagen by 170.6% in the 3rd quarter. Barclays PLC now owns 1,849,004 shares of the company's stock valued at $84,259,000 after buying an additional 1,165,594 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new position in Qiagen during the third quarter worth about $53,000. Tidal Investments LLC purchased a new stake in Qiagen during the 3rd quarter worth about $490,000. JPMorgan Chase & Co. boosted its holdings in Qiagen by 36.0% in the third quarter. JPMorgan Chase & Co. now owns 1,604,034 shares of the company's stock valued at $73,096,000 after acquiring an additional 424,937 shares during the last quarter. Finally, GAMMA Investing LLC lifted its position in shares of Qiagen by 170.1% during the fourth quarter. GAMMA Investing LLC now owns 1,518 shares of the company's stock worth $68,000 after purchasing an additional 956 shares in the last quarter. Institutional investors own 70.00% of the company's stock.

Analyst Ratings Changes

QGEN has been the topic of several recent research reports. Baird R W cut shares of Qiagen from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, February 19th. Redburn Atlantic downgraded shares of Qiagen from a "buy" rating to a "neutral" rating in a research report on Friday, April 4th. UBS Group cut their price objective on Qiagen from $50.00 to $48.00 and set a "neutral" rating for the company in a report on Friday, February 7th. Robert W. Baird increased their target price on shares of Qiagen from $42.00 to $43.00 and gave the stock a "neutral" rating in a report on Monday, April 21st. Finally, StockNews.com upgraded shares of Qiagen from a "buy" rating to a "strong-buy" rating in a report on Friday. Seven analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $48.42.

Qiagen Stock Performance

Qiagen stock traded up $0.02 during mid-day trading on Friday, reaching $42.18. The company's stock had a trading volume of 512,212 shares, compared to its average volume of 1,126,023. Qiagen has a twelve month low of $37.63 and a twelve month high of $49.30. The firm has a market cap of $9.38 billion, a price-to-earnings ratio of 117.45, a PEG ratio of 2.39 and a beta of 0.67. The business has a 50 day moving average price of $40.59 and a 200-day moving average price of $41.74. The company has a current ratio of 3.61, a quick ratio of 3.09 and a debt-to-equity ratio of 0.38.

Qiagen (NYSE:QGEN - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.55 EPS for the quarter, topping analysts' consensus estimates of $0.50 by $0.05. The company had revenue of $483.46 million during the quarter, compared to the consensus estimate of $465.66 million. Qiagen had a net margin of 4.23% and a return on equity of 13.92%. The firm's revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period last year, the firm earned $0.44 EPS. Sell-side analysts predict that Qiagen will post 2.26 EPS for the current fiscal year.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.